$26.550
+0.576 (+2.17%)At close
RELY News
RELY Events
Raises FY26 Adjusted EBITDA Outlook to $410M-$415M
Consensus $1.97B. Raises FY26 adjusted EBITDA view to $410M-$415M from $370M-$385M.
Sees Q3 Adjusted EBITDA of $410M-$415M
Sees Q3 adjusted EBITDA $410M-$415M.
Remitly Q2 Revenue Reaches $495.16M, Exceeds Expectations
Reports Q2 revenue $495.16M, consensus $485.97M. "We delivered another excellent quarter, achieving record revenue, Adjusted EBITDA, and net income, while surpassing 10 million quarterly active customers for the first time in our company's history, a direct reflection of the trust and confidence customers place in Remitly," said Sebastian Gunningham, Chief Executive Officer. "Our results reflect the compounding advantages of a trusted global network, a strategy that resonates with customers, and rigorous cost discipline. AI-driven operating efficiencies are creating additional capacity to invest in growth while improving margins, giving us more confidence in the opportunities ahead."
Remitly Secures SVF License from UAE Central Bank
Remitly Global secured a stored value facilities, or SVF, license with Exchange Business Category IV from the Central Bank of the UAE. This authorization further extends Remitly's regulated global footprint and our service to customers across more than 175 countries. With the license secured, Remitly will be able to bring new products built to serve UAE customers.
Remitly Global to Replace Apellis Pharmaceuticals
Remitly Global (RELY) will replace Apellis Pharmaceuticals (APLS). S&P 500 constituent Biogen (BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.